2025-10-04 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS), based on the data you provided.  I'll present the information in English with some brief analysis after each section, followed by a final summary.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** HIMS
*   **Company:** Hims & Hers Health Inc. (A telehealth company focused on providing personalized health and wellness solutions)
*   **HIMS Cumulative Return:** 244.52%
*   **VOO Cumulative Return:** 72.46%
*   **Absolute Divergence (HIMS - VOO):**
    *   Max: 321.5
    *   Min: -86.1
    *   Current: 207.0
*   **Relative Divergence:** 71.9

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) over the observed period.  The current divergence of 207% indicates substantial outperformance. The relative divergence of 71.9 suggests that HIMS' outperformance is positioned relatively high within its historical range compared to the S\&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR     | MDD   | Alpha   | Beta  | Cap(B) |
|------------|----------|-------|---------|-------|--------|
| 2019-2021  | -42.0%   | 74.4% | -81.0%  | 0.0   | 1.5    |
| 2020-2022  | -19.0%   | 78.6% | -18.0%  | -0.0  | 1.4    |
| 2021-2023  | -65.0%   | 78.6% | -67.0%  | -0.1  | 2.0    |
| 2022-2024  | 119.0%   | 79.4% | 98.0%   | -0.0  | 5.5    |
| 2023-2025  | 249.0%   | 80.8% | 186.0%  | 0.1   | 11.9   |

**Analysis:**

*   **CAGR:**  Shows strong growth in the most recent period (2023-2025), but significant losses in previous periods.  Volatile performance history.
*   **MDD (Maximum Drawdown):**  Consistently high, indicating significant risk and price volatility.
*   **Alpha:**  Significantly positive in the most recent period, indicating outperformance relative to its risk.  However, previously, it showed significant underperformance.
*   **Beta:**  Relatively close to zero, suggesting the stock's movement is not strongly correlated with the overall market.
*   **Cap(B):**  Market capitalization has increased significantly, especially recently.

**2. Recent Stock Price Movement**

*   **Current Price:** 52.54
*   **Previous Close:** 57.87
*   **Change:** -9.21
*   **5-Day Moving Average:** 56.089
*   **20-Day Moving Average:** 54.0122
*   **60-Day Moving Average:** 51.7179

**Analysis:**  The price has recently dropped sharply (-9.21). The current price is below the 5-day and 20-day moving averages but above the 60-day moving average.  This suggests a recent downward trend after a period of upward momentum.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 47.62 (Neutral)
*   **PPO:** -0.14 (Slightly oversold)
*   **Hybrid Signal:**  "cash_0%_Buy 100% of cash (17 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)" -  Recommends fully investing available cash and continuing to invest a small percentage monthly.
*   **Delta_Previous_Relative_Divergence (20-day change):** 3.3 (+) (Short-term increase)
*   **Significant Price Change:** The large negative change of -9.21 suggests a significant event or shift in market sentiment.
*   **Expected Return:** 1.6% (Long-term, S&P 500 Outperformance)

**Analysis:**

*   The MRI suggests that despite the recent price drop, the overall market conditions are still favorable for investment.
*   The RSI is neutral, indicating neither overbought nor oversold conditions before the recent drop.
*   The PPO is slightly negative, which can be interpreted as a potential buying opportunity.
*   The hybrid signal suggests a confident investment strategy.
*   The positive change in relative divergence indicates improving short-term momentum.

**4. Recent News & Significant Events**

*   **[2025-10-03] Why Hims & Hers Stock Slipped Today (Motley Fool)**
*   **[2025-10-03] Hims & Hers Expands Health Access Through Subscription Revenue Model (Zacks)**
*   **[2025-10-03] Evaluating Hims & Hers Health (HIMS) Valuation After 39% Share Price Surge in the Past Month (Simply Wall St.)**
*   **[2025-10-02] Breakout Stocks Watch: What Looms For October? (Investor's Business Daily)**
*   **[2025-10-02] agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know (StockStory)**
*   **[2025-10-01] OMCL or HIMS: Which Is the Better Value Stock Right Now? (Zacks)**

**Analysis:** The news is mixed. There's an article directly addressing the recent price slip. Other articles highlight the company's expansion and subscription model, and some discuss the stock's valuation after a recent surge. The comparison article (OMCL vs HIMS) is also relevant. This suggests the stock is being actively discussed and evaluated by market analysts.

**4-2. Analyst Opinions**

*   **Analyst Consensus:**  No Key Provided. The consensus is neutral, with 12 opinions.
*   **Target Price:** Average: 47.42, High: 85.00, Low: 25.00
*   **Recent Rating Changes:** No recent rating changes are indicated.

**Analysis:**  The analyst consensus is neutral, and the target price range is wide, reflecting uncertainty. The average target price is below the current price, suggesting potential downside risk, but the high target suggests significant potential upside. The absence of recent rating changes suggests analysts are holding their positions, for now.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2024-08-05 | 0.06 | 0.32 B$   |
| 2025-08-04 | 0.06 | 0.32 B$   |

**Analysis:**  Earnings per share (EPS) and revenue have fluctuated. Both EPS and revenue showed strong growth in the last two reported quarters (2025-08-04, 2025-05-05).

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.54B  | 76.39%        |
| 2025-03-31 | $0.59B  | 73.50%        |
| 2024-12-31 | $0.48B  | 76.81%        |
| 2024-09-30 | $0.40B  | 79.16%        |
| 2024-06-30 | $0.32B  | 81.30%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
|------------|---------|--------|
| 2025-06-30 | $0.56B  | 7.55%  |
| 2025-03-31 | $0.55B  | 9.01%  |
| 2024-12-31 | $0.48B  | 5.46%  |
| 2024-09-30 | $0.44B  | 17.18% |
| 2024-06-30 | $0.36B  | 3.67%  |

**Analysis:**

*   **Revenue:**  Shows consistent growth over the past several quarters.
*   **Profit Margin:**  Remains relatively high and stable, indicating strong operational efficiency.
*   **Equity:**  Increasing, reflecting the company's growing asset base.
*   **ROE (Return on Equity):** Fluctuates, but generally shows positive returns, although lower in recent periods.

**7. Overall Summary**

Hims & Hers Health Inc. (HIMS) has shown impressive revenue growth and high profit margins. The stock has significantly outperformed the S&P 500, but it has also exhibited high volatility, as reflected in its Maximum Drawdown and Alpha/Beta analysis.

The recent price drop (-9.21) is a cause for caution and aligns with recent news articles specifically discussing the stock's decline. While the Market Risk Indicator suggests favorable market conditions and the hybrid signal advocates for continued investment, the analyst consensus is neutral with a wide target price range, indicating uncertainty about the stock's future performance.

**Key Considerations:**

*   **Recent Price Drop:** Understand the reason behind the recent price decline by delving deeper into the news articles.
*   **Volatility:** Be aware of the stock's high volatility and risk tolerance.
*   **Analyst Uncertainty:**  The neutral analyst consensus and wide target price range suggest more research is needed to form a strong conviction.
*   **Long-Term Potential:** The company's strong revenue growth, high profit margins, and positive expected return suggest good long-term potential, but the path may be bumpy.

**Recommendation:**

Given the conflicting signals – strong fundamentals but recent price weakness and analyst uncertainty – a cautious approach is warranted. Before making any investment decisions, conduct further research into the reasons behind the recent price drop and carefully consider your risk tolerance. Monitor the stock's performance and news flow closely. A strategy of gradual accumulation (dollar-cost averaging) may be appropriate to mitigate risk.
